Protagonist Therapeutics
PTGX
PTGX
188 hedge funds and large institutions have $2.05B invested in Protagonist Therapeutics in 2024 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 63 increasing their positions, 68 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
7% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 68
2.2% less ownership
Funds ownership: 102.91% → 100.71% (-2.2%)
87% less call options, than puts
Call options by funds: $956K | Put options by funds: $7.56M
Holders
188
Holding in Top 10
8
Calls
$956K
Puts
$7.56M
Top Buyers
| 1 | +$31.7M | |
| 2 | +$29.8M | |
| 3 | +$28.4M | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$13.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.5M |
Top Sellers
| 1 | -$53.2M | |
| 2 | -$41.2M | |
| 3 | -$15.1M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$14M |
| 5 |
CAC
Cowen and Company
New York
|
-$13M |